Download the ESMO 2012 Abstract Book - Oxford Journals

More documents

Recommendations

Info

Annals of Oncology reduction and 38 patients received RT at the full dose. Three months after therapy completion tumor response was observed in 33 patients and after 2 years, 25 patients were in complete remission. Although treatment was accompanied with a rate of grate 3 and 4 toxicity of 30% during induction chemotherapy and up to 68% during radiotherapy with cetuximab, our treatment seems feasible. Toxicities resolved within 3 months after end of treatment and only two patients became dependent on gastric feeding tubes after two years, compared to 21 patients during treatment. We lost one patient because of treatment related toxicity and 73% of the 49 included patients finished treatment without dose reduction or delay of treatment. 2-year progression-free survival rate was 59% and 2-year overall survival rate was 63%, respectively. Conclusion: Concurrent radiotherapy plus cetuximab after three courses of induction chemotherapy was feasible and associated with promising complete remission, progression-free and overall survival rates. Further optimization of dose and sequence is warranted. Disclosure: All authors have declared no conflicts of interest. 1039P INDUCTION CHEMOTHERAPY USING DOCETAXEL, CISPLATIN AND FLUOROURACIL (TPF) FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY VS THE SAME CONCOMITANT CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (LASCCHN) W. El-Sadda, I. Abdel Halim, K. Abul Khair, R. Abdel Latif Clinical Oncology and Nuclear Medicine, Mansoura University Hospital School of Medicine, Mansoura, EGYPT Background: Concomitant chemoradiotherapy (CCRT) with cisplatin is considered a standard treatment of LASCCHN. The role of induction chemotherapy (IC) followed by CCRT remains controversial. Our aim was to compare neoadjuvant chemotherapy with 3 cycles of TPF followed by CCRT to CCRT alone. The 1ry objective of the study was ORR and the 2ry objectives were toxicity, PFS and OS. Patients and methods: Between 2006 & 2008, 100 patients with histologically proven SCC of the Head & Neck (stage IIB-IVA) were enrolled. WHO PS 0-1, with adequate bone marrow, liver and kidney functions. Fifty patients received 3 cycles of IC including docetaxel 75 mg/m 2 IV over 1h D1, cisplatin 75mg/m 2 IV over 3h D1 and 5-FU 750 mg/m 2 IV continuous infusion over 24h D1-5 (repeated every 3 wks). Premedications before and after docetaxel and cisplatin with prophylactic antibiotic on D5 and G-CSF on D6. This was followed by CCRT in the form of radiotherapy using conventional fractionation (2Gy/day, 5 fr/week, total dose of 70Gy) with concurrent weekly cisplatin 20 mg/m 2 IV (Gp A). In gp B, patients received CCRT alone. Response was assessed by physical examination, CT scan and endoscopy after 2 cycles, after completion of IC, and 6-8 wks after completion of CCRT. Results: All patients in both gps had completed the treatment schedule and were evaluable for response, toxicity and survival. The median age was 44.5 years in both gps (range 27-62). Seventy percent of patients had PS 0, 65 patients had cervical LN involvement (N 2-3). The ORR after the completion of CCRT were 88% & 68% in the two groups respectively. Toxicity was manageable in both groups. The main severe toxicities during IC were G3 alopecia and neutropenia. During CCRT, the most severe side effects in both groups were mucositis and weight loss. The 2-year PFS and OS rates were 70%, 86% and 75%, 80% respectively. Conclusion: Induction chemotherapy using TPF followed by CCRT is safe, tolerable and effective treatment and can significantly improve survival in patients with LASSCHN. Disclosure: All authors have declared no conflicts of interest. 1040P THE IMPACT OF INDUCTION CHEMOTHERAPY ON CISPLATION DOSE INTENSITY DURING CHEMO-RADIOTHERAPY (CTRT) IN OROPHARYNGEAL SQUAMOUS CELL CANCER (OPC) R. Granata 1 , P. Bossi 1 , E. Orlandi 2 , L. Locati 1 , C. Bergamini 1 , C. Resteghini 1 , T. Ibba 3 , G. Scaramellini 3 , C. Fallai 2 , L. Licitra 1 1 Head & Neck Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, ITALY, 2 Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, ITALY, 3 Otorhinolaryngology Unit, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, ITALY Background: Induction (IC) with TPF (Taxotere, Cisplatin, 5-FU) has been associated with improved outcome in advanced head and neck squamous cell cancer patients (pts). Full dose of cisplatin (300 mg/m 2 ) during CTRT has been demonstrated to impact on patients’ outcome. The aim of the current study is to investigate whether the IC could impact on cisplatin dose intensity during CTRT in a homogeneous population of OPC. Materials and methods: The study population consisted of 101 pts with stage III-IV OPC treated from 07/2004 to 12/2011 with IC (n = 53) plus CTRT or CTRT alone (n= 48). IC consisted of TPF, while weekly 50 mg/m 2 or 3-weekly 100 mg/m 2 cisplatin was administered concurrently with RT (planned chemotherapy dose = 300 mg/m 2 ; planned RT dose = 66-70 Gy, 3DRT or IMRT with a conventional or accelerated fractionation). Carboplatin substituted cisplatin in case of creatinine clearance less than 60 mL/min. HPV status, concurrent cisplatin dose intensity and RT overall treatment time (OTT) were analyzed. Results: Stage IV pts were 100% in the IC group and 83% in CTRT, while HPV positive OPCs were detected in 58% and 63% of the cases respectively. TPF median number of cycles was 3, with induction cisplatin median dose administered of 200 mg/ m 2 . RT median total dose administered was 70 Gy in both group. Accelerated fractionated RT was adopted in 65% of CTRT alone group and in 21% of IC group. Two pts (1 in each group) did not complete CTRT because of cardiovascular events. Mean and median dose intensity of cisplatin concurrent to RT in the IC group was 77.7% and 75% (35%-100%) while in CTRT group was 86% and 91.7% (33%-100%), with a p value = 0.014. In 11 pts (21%) treated with IC and only in 1 pts (2%) treated with CTRT alone cisplatin was substituted with carboplatin. No different cisplatin dose intensity was identified in HPV positive versus HPV negative cases. Prolonged OTT (longer than 5 days) was observed in two patients in IC group due to sepsis and severe mucositis as well as in one patient in CTRT group due to machine failure. Conclusions: Concurrent cisplatin dose intensity was significantly reduced in pts receiving IC compared to CTRT alone, irrespective of HPV status. Whether this has an impact on the results of IC followed by full dose CT/RT has to be clarified. Disclosure: All authors have declared no conflicts of interest. 1041P THE TOLERANCE OF TPF CHEMOTHERAPY REGIME STANDARD OR MODIFIED IN HEAD NECK CANCER PATIENTS OVER 65 YEARS OLD S.M. Ilie 1 , I. Ruginescu 2 , E. Saada 2 , F.R. Ferrand 2 , A. Schilf 2 , F. Janot 2 , J. Guigay 2 1 Medical Oncology, Institute of Oncology Bucharest, Fundeni Clinical Hospital Alexandru Treistoreanu, Bucharest, ROMANIA, 2 Head and Neck Cancer Treatment, Institute Gustave Roussy, Villejuif, FRANCE Background: Docetaxel, Cisplatin, 5FU regimen (TPF) has became a standard for induction chemotherapy in locally advanced squamous cell cancer of head and neck (SCCHN). However, little is known about tolerance and efficacy of TPF in older patients Objective of the study was to evaluate the tolerance of induction chemotherapy with TPF regimen in SCCHN patients over 65 years, looking for side effects especially degree 3 and 4. Materials and methods: retrospective study of the database of Head and Neck Cancer Department of Gustave Roussy Institute between 2006 and 2009: all patients over 65 years who received a TPF induction chemotherapy were included. Results: Among 300 patients treated with TPF induction chemotherapy, we found 57 pts over 65 years : 41 (70%)between 65 - 70, 9 (15%)between 70 - 75 and 7 (12%) over 75. Most of patients received an organ preservation treatment for T3N0-1M0 hypopharynx and larynx cancer (52%) . 30 pts had an impaired nutritional status and 37(64%) an ACE 27 index superior of 2. 40 pts (70%) accomplished their planed cycles but only 37( 65%) received the planed doses. 23 pts (41%) presented a grade 3 or 4 hematological or gastrointestinal adverse events and 5 toxic deaths were observed. Conclusion: This retrospective study confirms the high risk of toxicity of induction chemotherapy with TPF combination in elderly SCCHN patients that may compromise the postsurgical outcome in patients over 65 years presenting at least one comorbidity and denutrition. Geriatric assessment is probably useful in this population to better select candidates to induction chemotherapy. Disclosure: All authors have declared no conflicts of interest. 1042P SERIAL COMPREHENSIVE GERIATRIC EVALUATION IN ELDERLY HEAD AND NECK CANCER PATIENTS UNDERGOING RADIOTHERAPY P.R. Debruyne 1 , M. Lycke 1 , T. Boterberg 2 , H. Pottel 3 , L. Goethals 1 , N. van den Noortgate 4 , F. Duprez 2 , S. Rottey 5 , K. Kargar-Samani 6 , L. Pottel 1 1 Campus Loofstraat - Cancer Center, General Hospital Groeninge, Kortrijk, BELGIUM, 2 Department of Radiation Oncology, Ghent University Hospital, Ghent, BELGIUM, 3 Department of Biostatistics, Catholic University Leuven KULAK, Kortrijk, BELGIUM, 4 Department of Geriatrics, Ghent University Hospital, Ghent, BELGIUM, 5 Department of Medical Oncology, Ghent University Hospital, Ghent, BELGIUM, 6 Department of Medical Oncology, Centre Hospitalier de Wallonie Picarde, Tournai, BELGIUM Background: Elderly head and neck (H&N) cancer patients can present with significant co-morbidities whilst treatment induces additional morbidity. Comprehensive geriatric assessment (CGA) has been proposed as a key treatment approach in elderly cancer patients. We studied the feasibility of serial CGA during radiotherapy in this population. Material and methods: Patients aged ≥ 65 years with primary H&N cancer undergoing curative radiotherapy (with or without systemic treatment), were Volume 23 | Supplement 9 | September 2012 doi:10.1093/annonc/mds402 | ix341
evaluated by the screening instruments Vulnerable Elders Survey-13 (VES-13) and G8, and CGA, at baseline and in the 4 th week of their treatment at General Hospital Groeninge or Ghent University Hospital. Results: Ninety eligible patients with a median age of 72 (range 65-87) consented. Patients mostly presented with an advanced stage tumour (67.8%, stage III-IV) of the larynx (46.7%) and pharynx (32.2%). Thirteen patients declined assessment in the 4 th week of therapy. Of those patients, one withdrew from further study participation, one died and in two patients, a change of therapeutic intent was indicated. Nine patients declined because they felt too ill. At baseline, 40.3%, 64.9% and 71.4% of patients were defined vulnerable, based on respectively VES-13 (cut-off ≥3), G8 (cut-off ≤14) and CGA (defined as impairments in two or more domains). Significantly more patients were considered vulnerable at week 4 by VES-13 (55.8%, P < 0.0001), G8 (90.9%, P < 0.0001) and CGA (81.8%, P < 0.05). Patients presented with deficits in the following domains: co-morbidity (CIRS-G), nutrition (MNA), community functioning (IADL), physical status (Tinetti), self-care (ADL), emotional wellbeing (GDS) and cognition (MMSE) at both points in time. In addition, the incidence of vulnerability in all health domains increased during treatment, with especially deterioration of nutritional (P < 0.0001), functional (P < 0.0001), mental (P < 0.01) and emotional (P < 0.01) status. Conclusion: Serial CGA identifies multidimensional health problems and their evolution during radiotherapy. It indicates the need for re-evaluation of a patient’s health status and could guide intensive supportive care in elderly patients treated for H&N cancer. Acknowledgement: Our work is supported by a grant from the Belgian Government, National Cancer Plan (NKP_024_018). Disclosure: All authors have declared no conflicts of interest. 1043P PHASE II STUDY OF BIWEEKLY DOSE-INTENSE PACLITAXEL PLUS GEMCITABINE (GEM/TAX) IN PATIENTS WITH RECURRENT LOCOREGIONAL OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA A. Sukari1 , M. Salem1 , M. Al-Hajeili1 , J. Jacobs2 , S. Taylo1 ,G.Yoo2 , H. Lin2 , L. Heilbrun1 , A. Alousi3 , O. Kucuk4 1 Oncology, Karmanos Cancer Center, Wayne State University, Detroit, MI, UNITED STATES OF AMERICA, 2 Department of Otolaryngology and Head and Neck Surgery, Karmanos Cancer Center, Wayne State University, Detroit, MI, UNITED STATES OF AMERICA, 3 Division of Hematology and Oncolog, MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA, 4 Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, UNITED STATES OF AMERICA Background: Patients with metastatic head and neck squamous cell carcinoma (HNSCC) have a poor prognosis, limited treatment options, and median survival of 6 to 9 months. Paclitaxel (TAX) and gemcitabine (GEM) have both shown activity in HNSCC. The optimal combination, dosing, and scheduling of both drugs is, however, unknown. Thus, we investigated the efficacy and safety of biweekly dose-intense GEM/TAX in patients with recurrent locoregional or metastatic HNSCC. Methods: An open-label, single-institution, single-arm, phase II study was conducted for patients (pts) who were previously treated with no more than two cytotoxic regimens. The pts received paclitaxel (150 mg/m 2 IV) and gemcitabine (3000 mg/m 2 IV) on day 1 and 15. The treatments were repeated every 28 days (one cycle), until disease progression or unacceptable toxicity. The primary end point was response rate. RECIST-defined response was evaluated every 2 cycles (8 wks) and toxicities were evaluated after each cycle (4 wks). Results: Fifty-five pts were enrolled into the trial (M: F 42:13, median age (range): 56 years (23-84), performance status 0-2, 48 pts had previous radiation therapy and 39 had previous surgery), 41 of whom were response evaluable. Of these 41 patients, two pts (4.8%) achieved complete response (CR) and 17 (41.4%) demonstrated a partial response (PR). Thus, the overall response rate was 46%. Thirteen pts (31.7%) had stable disease (SD), resulting in tumor control in 32 of 41 pts (78% with CR, PR or SD), whereas 9 pts (21.1%) had disease progression (PD). Among those pts who achieved objective response or stable disease, the median response duration was 5 months and median time to progression was 4 months. Median overall survival (OS) was 15 months. Myelosuppression was the most common adverse event. Grade 3-4 neutropenia and anemia were observed in 5 (12%) and 11 (26%) pts, respectively. Eight (19%) pts developed grade 3 infection. None of these pts, however, had febrile neutropenia and there were no treatment-related deaths. Conclusions: The combination of biweekly dose intense GEM/TAX was tolerable and active regimen in patients with recurrent locoregional or metastatic HNSCC. Our findings warrant further investigation in a larger patient population. Disclosure: All authors have declared no conflicts of interest. Annals of Oncology 1044P PHASE IB TRIAL OF IMO-2055 IN COMBINATION WITH 5-FU, CISPLATIN AND CETUXIMAB IN 1ST-LINE PTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) J.P. Machiels 1 , M.C. Kaminsky 2 , U. Keller 3 , T.H. Brümmendorf 4 , T. Goddemeier 5 , U. Forssman 6 , J.P. Delord 7 1 Medical Oncology, Cliniques Universitaires St. Luc, Brussels, BELGIUM, 2 Département d’Oncologie Médicale, Centre Alexis Vautrin, Nancy, FRANCE, 3 III. Medizinische Klinik, TU München, Munich, GERMANY, 4 Hämatologie und Onkologie, Universitätsklinikum Aachen, Aachen, GERMANY, 5 Global Clinical Operations / Global Biostatistics, Merck KGaA, Darmstadt, GERMANY, 6 Global Clinical Development Unit Oncology, Merck Serono S.A, Geneva, SWITZERLAND, 7 Clinical Resarch Unit, Centre Claudius-Regaud, Toulouse, FRANCE Purpose: IMO-2055 is a toll-like receptor 9 agonist with potential to enhance the efficacy of antitumor agents through immune stimulation. Methods: IMO-2055 was administered to 1st-line pts with R/M SCCHN on days 1, 8 and 15 of each 3-wk cycle in combination with 5-FU, cisplatin and cetuximab. IMO-2055 doses were to be escalated (3 + 3 design) from dose level (DL) 1 (0.16 mg/ kg) to DL2 (0.32 mg/kg) and DL3 (0.48 mg/kg) if
Page 1 and 2:
Annals of Oncology www.annonc.oxfor
Page 3 and 4:
subscriptions A subscription to Ann
Page 6 and 7:
Annals of Oncology Official Journal
Page 8 and 9:
The European Society for Medical On
Page 10 and 11:
Audit Committee Chair: Fortunato Ci
Page 12 and 13:
Familial cancer Judith Balmaña, Ba
Page 14 and 15:
ESMO 2012 Congress Travel Grants 47
Page 16 and 17:
Exhibitors The following companies
Page 18 and 19:
ESMO Fellowships, 1989-2011 The Eur
Page 20:
Ondrej Gojis, Czech Republic 2008-2
Page 23 and 24:
abstracts hpv biology and implicati
Page 25 and 26:
abstracts the characterization of l
Page 27 and 28:
abstracts description of intra-tumo
Page 29 and 30:
prevent cell death. It is anticipat
Page 31 and 32:
22IN TARGETING THE HOST IN TNBC G.
Page 33 and 34:
abstracts a paradigm shift in early
Page 35 and 36:
abstracts how can medical oncologis
Page 37 and 38:
feasibility), but by how high the c
Page 39 and 40:
abstracts re-inventing the medical
Page 41 and 42:
abstracts emerging diagnostic and t
Page 43 and 44:
abstracts biologically based treatm
Page 45 and 46:
abstracts molecular targets in mali
Page 47 and 48:
abstracts melanoma therapy: from fr
Page 49 and 50:
diagnosis and can also be used for
Page 51 and 52:
analysis at 11 months median follow
Page 53 and 54:
mouse model of Kras mutant NSCLC. I
Page 55 and 56:
abstracts subtyping soft tissue sar
Page 57 and 58:
abstracts key topics in supportive
Page 59 and 60:
ESMO-CSCO Joint Symposium: Building
Page 61 and 62:
ESMO-EANM-ESR Joint Symposium: Imag
Page 63 and 64:
ESMO-ESTRO Joint Symposium: Innovat
Page 65 and 66:
ESMO-MASCC Joint Symposium: Integra
Page 67 and 68:
ESO Society Symposium: Celebrating
Page 69 and 70:
Results: TIMP-1 expression was incr
Page 71 and 72:
will benefit from this targeted the
Page 73 and 74:
cytomegalovirus (CMV). Analysis of
Page 75 and 76:
functional consequences of Endoglin
Page 77 and 78:
elationship between the ROR score,
Page 79 and 80:
183P EPIDERMAL GROWTH FACTOR RECEPT
Page 81 and 82:
Plasma adiponectin level on the pre
Page 83 and 84:
Table: 198P PFS OS Median, mo HR Me
Page 85 and 86:
204P EVALUATION OF PTEN AND PIK3CA
Page 87 and 88:
Material and methods: We searched P
Page 89 and 90:
Results: The median concentration o
Page 91 and 92:
Table: 226P Methods: Pts were rando
Page 93 and 94:
However, additional analysis sugges
Page 95 and 96:
number of biomarkers have been trie
Page 97 and 98:
Table: 248O 249PD PROTEOMIC PREDICT
Page 99 and 100:
Conclusions: BW and serum Ctrough o
Page 101 and 102:
261P BREAST CANCER SUBTYPES AND OUT
Page 103 and 104:
90 mg/m2-cyclophophamide 600 mg/m2
Page 105 and 106:
to 9 weeks after dosing. Trastuzuma
Page 107 and 108:
Patients and methods: We reviewed d
Page 109 and 110:
sector patients. The aim of this st
Page 111 and 112:
Linear Logistic Model with Relaxed
Page 113 and 114:
Results: The median CTC fold change
Page 115 and 116:
312: Table: Chemotherapy uptake wit
Page 117 and 118:
abstracts breast cancer, locally ad
Page 119 and 120:
Results: 8 trials (2092 pts) with 1
Page 121 and 122:
absolute difference of median value
Page 123 and 124:
Novartis, Genentech, and sanofi-ave
Page 125 and 126:
Results: Three RCTs with 1023 patie
Page 127 and 128:
collected from all patients for det
Page 129 and 130:
355P FIRST REPORT OF LONG-TERM RESP
Page 131 and 132:
361P A RETROSPECTIVE ANALYSIS OF PL
Page 133 and 134:
publications and aggregated in a me
Page 135 and 136:
Thus the primary aim to target BCSC
Page 137 and 138:
383 WHY DO WOMEN WITH BREAST CANCER
Page 139 and 140:
Results: We evaluated 76 pts with M
Page 141 and 142:
more than 6 cycles of capecitabine.
Page 143 and 144:
406TiP PHASE II TRIAL OF PRIMARY SY
Page 145 and 146:
abstracts CNS tumors 410O CONDITION
Page 147 and 148:
Conclusions: Our data suggested tha
Page 149 and 150:
Conclusions: As in other cancer typ
Page 151 and 152:
432 GAMMA KNIFE RADIOSURGERY AS A M
Page 153 and 154:
abstracts developmental therapeutic
Page 155 and 156:
1PR), but no responses were seen in
Page 157 and 158:
RO and Cd, as well as PD data for c
Page 159 and 160:
and vulvar Ca), and 11 SDs were obs
Page 161 and 162:
knowing HLA-A status double-blindly
Page 163 and 164:
Acquired-resistance to EGFR inhibit
Page 165 and 166:
474P PHASE 1 STUDY OF THE SELECTIVE
Page 167 and 168:
TST is active in breast and gastric
Page 169 and 170:
Treatment-induced shedding of circu
Page 171 and 172:
Methods: Either co-cultures of peri
Page 173 and 174:
501 PRECLINICAL DATA INVESTIGATING
Page 175 and 176:
509TiP LUX-LUNG 8: A RANDOMIZED, OP
Page 177 and 178:
(P = 0.64). Synchronous BBC was sig
Page 179 and 180:
abstracts gastrointestinal tumors,
Page 181 and 182:
Disclosure: M. Lee: I am an employe
Page 183 and 184:
plus intravenous Bev(7.5mg/kg q 21d
Page 185 and 186:
anti-EGFR treatment. The present st
Page 187 and 188:
patients harboring a T/T genotype t
Page 189 and 190:
551P ADJUVANT CHEMOTHERAPY (AC) USE
Page 191 and 192:
experienced significantly more ≥
Page 193 and 194:
functioning scales. Exploratory ana
Page 195 and 196:
oxaliplatin (100 mg/m 2 )/raltitrex
Page 197 and 198:
572P PANERB STUDY: WHICH CATEGORY O
Page 199 and 200:
Results: 92/114 patients were preop
Page 201 and 202:
585P CHANGES IN THE INTESTINAL ENVI
Page 203 and 204:
592P PHASE II TRIAL OF COMBINED CHE
Page 205 and 206:
minutes. In a previous study, 30-mi
Page 207 and 208:
Patients and methods: Chemotherapy-
Page 209 and 210:
612P ARE PATIENTS WITH RESECTABLE R
Page 211 and 212:
Conclusions: AMPK and ACC activatio
Page 213 and 214:
of surgical monotherapy in patients
Page 215 and 216:
Table: 632 633 AFLIBERCEPT/FOLFIRI
Page 217 and 218:
factors play the determining role i
Page 219 and 220:
Abstract withdrawn in exceptional c
Page 221 and 222:
were respectively 10.6 vs 8.5 vs 3.
Page 223 and 224:
Results: 20 gastrointestinal cancer
Page 225 and 226:
abstracts gastrointestinal tumors,
Page 227 and 228:
Day 8. A second identical course wa
Page 229 and 230:
proven in stage I GC. The aim of th
Page 231 and 232:
Conclusions: Longer OS to FOLFOX wa
Page 233 and 234:
692P PRELIMINARY SAFETY DATA FROM A
Page 235 and 236:
subgroup. Taking into consideration
Page 237 and 238:
Results: Three years of adjuvant im
Page 239 and 240:
considered sufficient to give an 80
Page 241 and 242:
721P FIRST-LINE TREATMENT WITH FOLF
Page 243 and 244:
after Gem-based therapy. The additi
Page 245 and 246:
735P RADIOGRAPHIC PARAMETERS IN PRE
Page 247 and 248:
validate the revised AJCC 7th stagi
Page 249 and 250:
Results: Among 862 MM we identified
Page 251 and 252:
Results: Frequently reported advers
Page 253 and 254:
gastric cancer patients with CNS me
Page 255 and 256:
discriminate the prognosis of HCC p
Page 257 and 258:
prospective, non-interventional stu
Page 259 and 260:
abstracts genitourinary tumors, non
Page 261 and 262:
787O EXTERNAL VALIDATION OF THE ASS
Page 263 and 264:
patient preference for P over S, an
Page 265 and 266:
798PD OPEN-LABEL PHASE II TRIAL OF
Page 267 and 268:
Hb, PS and LM. Median PFS for patie
Page 269 and 270:
may have led to reduced dose and sh
Page 271 and 272:
Results: 1,622 patients were identi
Page 273 and 274:
RCC) was designed to address an unm
Page 275 and 276:
Patients and methods: This is a sin
Page 277 and 278:
treatment at week 4, and week 12 by
Page 279 and 280:
effective in second or further line
Page 281 and 282:
Conclusions: In pts with RCC treate
Page 283 and 284:
using Drug inCode ® pharmacogeneti
Page 285 and 286:
Table: 857P standard, but is not av
Page 287 and 288:
efused HDCT. Of 23 patients, 20 com
Page 289 and 290:
we identified 49 and 220 patients w
Page 291 and 292: 879 TREATMENT OF PATIENTS WITH META
Page 293 and 294: Median overall survival (OS) was 26
Page 295 and 296: abstracts Genitourinary tumors, pro
Page 297 and 298: and week 13 BPI-SF Q3 scores), 28%
Page 299 and 300: Working Group (PCWG)-2 guidelines r
Page 301 and 302: atio HR 0.39; CI 0.18, 0.83, p = 0.
Page 303 and 304: We observed tumor responses and pro
Page 305 and 306: Here we report emerging data from t
Page 307 and 308: 928P LHRH AGONIST-INDUCED SUPPRESSI
Page 309 and 310: Disclosure: S. Oudard: Has acted as
Page 311 and 312: 939P NEOADJUVANT SIPULEUCEL-T IN LO
Page 313 and 314: 945 BONE TURNOVER MARKERS AND POTEN
Page 315 and 316: 952 SEQUENTIAL ANDROGEN DEPRIVATION
Page 317 and 318: managed in a multidisciplinary (MD)
Page 319 and 320: or hypercalcemia at screening; prio
Page 321 and 322: meeting. The prevalence of LGSC is
Page 323 and 324: Table: 975PD Continued AMG 386 + pa
Page 325 and 326: physicians in the U.S. and Europe.
Page 327 and 328: 989P PHASE II STUDY OF COMBINATION
Page 329 and 330: elated with stage, nodal involvemen
Page 331 and 332: 1004P CASE CONTROL STUDY ON TWO DIF
Page 333 and 334: eight patients who had infertility
Page 335 and 336: abstracts head and neck cancer 1016
Page 337 and 338: same CT/RT; Arm B2: 3 cycles of ind
Page 339 and 340: induction chemotherapy in the treat
Page 341: patients. We have developed a rando
Page 345 and 346: morbidities that radiation would le
Page 347 and 348: Conclusions: Through adequate selec
Page 349 and 350: abstracts hematological malignancie
Page 351 and 352: anthracyclines in vitro. A favorabl
Page 353 and 354: 1076P RITUXIMAB PLUS SUBCUTANEOUS C
Page 355 and 356: than the standard target of ≥2.5
Page 357 and 358: Patients: From November 2002 to May
Page 359 and 360: lymphadenopathy and multiple cutane
Page 361 and 362: prospective non-interventional stud
Page 363 and 364: Funding: GSK Biologicals Disclosure
Page 365 and 366: survival rates of 13-25% (Prieto et
Page 367 and 368: high response rates and prolonged p
Page 369 and 370: GlaxoSmithKline, Merck Sharp & Dohm
Page 371 and 372: advisor for Merck Sharp & Dohme, an
Page 373 and 374: or cutaneous melanoma. A survival u
Page 375 and 376: systemic therapy or were intolerant
Page 377 and 378: abstracts neuroendocrine tumors and
Page 379 and 380: morbidity, with G3 tumors behaving
Page 381 and 382: pts. Poorly differentiated endocrin
Page 383 and 384: Adenocarcinoma was present in 25 pa
Page 385 and 386: Method: Endobronchial ultrasound gu
Page 387 and 388: widely used by single agent or plat
Page 389 and 390: disease after surgery were treated
Page 391 and 392: stage IIIA NSCLC, EML4-ALK fusion-p
Page 393 and 394:
1200P CONCOMITANT CHEMORADIATION GI
Page 395 and 396:
Patients and methods: The study was
Page 397 and 398:
months (95% CI:13-25). The PFS and
Page 399 and 400:
maintenance therapy had favourable
Page 401 and 402:
abstracts non-small cell lung cance
Page 403 and 404:
Ingelheim, GSK Biologicals (compens
Page 405 and 406:
1234PD RANDOMIZED PHASE III TRIAL O
Page 407 and 408:
GlaxoSmithKline (myself, compensate
Page 409 and 410:
1243P IDENTIFICATION OF MICRORNA (M
Page 411 and 412:
N-arm n=34 P-arm n=32 All n=66 Male
Page 413 and 414:
1255P POPULATION BASED EVALUATION O
Page 415 and 416:
1262P DISTINCT SPREAD OF EGFR MUTAT
Page 417 and 418:
1268P VISUAL DISTURBANCES IN PATIEN
Page 419 and 420:
MERCK SERONO: Advisor, speaker in s
Page 421 and 422:
Conclusions: These data from SAiL a
Page 423 and 424:
NSCLC diagnosis and time of BM diag
Page 425 and 426:
1291P PHASE I/II DOSE-FINDING STUDY
Page 427 and 428:
Network utilization of WBCGF in the
Page 429 and 430:
1303P COST EFFECTIVENESS OF PEMETRE
Page 431 and 432:
Results: The patients’ characteri
Page 433 and 434:
EGFR mut at exons 18, 19, 21, and K
Page 435 and 436:
Methods: EML4-ALK fusion was screen
Page 437 and 438:
Results: The median survival time (
Page 439 and 440:
enefit from sustained EGFR blockade
Page 441 and 442:
epresented by 19 pts (32%) female,
Page 443 and 444:
and at least one prior course of ch
Page 445 and 446:
Methods: NSCLC patients with radiog
Page 447 and 448:
1367TiP LONG-TERM ERLOTINIB THERAPY
Page 449 and 450:
Austria, Czech Republic, Finland, G
Page 451 and 452:
were every 6 weeks (wk) (S1), every
Page 453 and 454:
Advantage enrollees (83% vs. 25%) [
Page 455 and 456:
Results: Based on 10,000 simulation
Page 457 and 458:
cancer tumors 12%, Germ cell tumor
Page 459 and 460:
Material and methods: 50 lung cance
Page 461 and 462:
1414TiP IMPLEMENTATION OF CANCER RE
Page 463 and 464:
abstracts palliative care 1422O EFF
Page 465 and 466:
Method and results: A total of 317
Page 467 and 468:
1436P SURVEY ON MODELS OF INTEGRATI
Page 469 and 470:
care unit (PCU) at the National Can
Page 471 and 472:
Characteristic No. % Total 63 1 st
Page 473 and 474:
hysterectomised-9.10% and cervix ca
Page 475 and 476:
abstracts psycho-oncology 1462PD IN
Page 477 and 478:
events, tumour response, and surviv
Page 479 and 480:
abstracts sarcoma 1477O ADHESION TO
Page 481 and 482:
1481PD A PHASE II STUDY OF DOVITINI
Page 483 and 484:
1488P ORGANISATION OF SARCOMA PATIE
Page 485 and 486:
Patients and methods: From August 2
Page 487 and 488:
chemotherapy respectively. At a med
Page 489 and 490:
of this group Those with relapsed d
Page 491 and 492:
1515 PREDICTORS OF SURVIVAL IN ADOL
Page 493 and 494:
abstracts small cell lung cancer an
Page 495 and 496:
emaining receiving either CAV or to
Page 497 and 498:
1533P EXPRESSION OF WILM⍰TUMOUR G
Page 499 and 500:
more than 3 months after first line
Page 501 and 502:
lower recurrence rate of NE. Pegfil
Page 503 and 504:
egimens (HR = 2.5, p < 0.001). Phys
Page 505 and 506:
1561P PREDICTIVE DIAGNOSTICS FOR RE
Page 507 and 508:
Methods: A prospective multicentre
Page 509 and 510:
Table: 1574P Pharmacokinetic parame
Page 511 and 512:
Novartis and unrestricted research
Page 513 and 514:
studies have shown that chemotherap
Page 515 and 516:
(Grade 1) and moderate to severe (G
Page 517 and 518:
declined to relatively lower level
Page 519 and 520:
1609P PHYSICAL ACTIVITY (PA) AND PH
Page 521 and 522:
patients were admitted to the oncol
Page 523 and 524:
Dicarbamin 100 mg/day on day 5 befo
Page 525 and 526:
Results: Anemia was detected in 83.
Page 527 and 528:
important to carry out randomized s
Page 529 and 530:
abstracts translational research 16
Page 531 and 532:
expression. Then, we analyzed PB sa
Page 533 and 534:
Table: 1657P TH BV + TH HR (95% CI)
Page 535 and 536:
BRAF mutations. Circulating free DN
Page 537 and 538:
1671P PHASE I CLINICAL TRIAL OF CAN
Page 539 and 540:
1678P PREDICTIVE VALUE OF TWO PHENO
Page 541 and 542:
theorized that the PI3K/AKT pathway
Page 543 and 544:
Material and methods: 101 patients
Page 545 and 546:
overexpressing and 232 had triple n
Page 547 and 548:
author index author index A Aamdal
Page 549 and 550:
author index Badran A. ix288 (874)
Page 551 and 552:
author index Bösmüller H. ix209 (
Page 553 and 554:
author index Chen A. ix319 (966O) C
Page 555 and 556:
author index De Droogh E. ix452 (13
Page 557 and 558:
author index Esposito G. ix209 (618
Page 559 and 560:
author index Geiges G. ix306 (930P)
Page 561 and 562:
author index Hartono S. ix70 (155P)
Page 563 and 564:
author index Iwasaki H. ix542 (1694
Page 565 and 566:
author index Kodaira M. ix90 (228P)
Page 567 and 568:
author index Lichtensztejn D. ix350
Page 569 and 570:
author index Martinez A. ix496 (153
Page 571 and 572:
author index Morishita N. ix432 (13
Page 573 and 574:
author index Okamoto N. ix432 (1320
Page 575 and 576:
author index Piau S. ix456 (1401P)
Page 577 and 578:
author index Rodríguez Rodríguez
Page 579 and 580:
author index Scoggins C.R. ix371 (1
Page 581 and 582:
author index Stern L. ix272 (823P)
Page 583 and 584:
author index Trypaki M. ix429 (1308
Page 585 and 586:
author index Whitmore J.B. ix310 (9
Page 587 and 588:
subject index subject index A AAV-H
Page 589 and 590:
subject index ix115 (316TiP), ix116
Page 591 and 592:
subject index diffuse large B-cell
Page 593 and 594:
subject index (1033P), ix340 (1036P
Page 595 and 596:
subject index medical information,
Page 597 and 598:
subject index (612P), ix214 (633),
Page 599 and 600:
subject index RCC, ix274 (830P) re-
Page 601 and 602:
subject index TR-FRET, ix84 (206P)
Page 603 and 604:
drug index drug index 1248P, 1250P,
Page 605 and 606:
translational research index transl
Page 607 and 608:
Page 609:
show all

Download the ESMO 2012 Abstract Book - Oxford Journals

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?